TICKERNERD
Menu
LABTHealthcare · Biotechnology

LABT Stock Forecast: Lakewood-Amedex Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$2.12

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 14 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.3M
Ticker Nerd rank
21 / 100
Median analyst target
$12
Analysts covering
0
Revenue$0.0
Operating income−$3.8M
Net income−$3.8M
Free cash flow−$2.1M
Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

LABT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lakewood-Amedex Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
21 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
96
Issuance
90
Accruals
70
Revisions
31
Value
15
Quality
14
Momentum
9
Growth
8
Volatility
1

Size (96): Smaller than most of the companies we track.

Volatility (1): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LABT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LABT, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LABT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LABT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Lakewood-Amedex Biotherapeutics, Inc. (LABT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.8×

Cheaper than 81% of US stocks

Price / sales
—
Price / book
1.1×

Cheaper than 70% of US stocks

EV / EBITDA
−0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−402.8%

Higher than 4% of US stocks

Return on assets
−139.4%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Lakewood-Amedex Biotherapeutics, Inc. (LABT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lakewood-Amedex Biotherapeutics, Inc. has a market value of $5.3M and an enterprise value of $778K.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$7.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$3.5M.

  • Shares outstanding: 2.2M.

  • Trailing P/E: −0.8×; forward P/E: −1.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Lakewood-Amedex Biotherapeutics, Inc. employs 5 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

LABT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LABTLakewood-Amedex Biotherapeutics, Inc.$5.3M
21
HCWBHCW Biologics Inc.$4.9M
63
MLECMoolec Science SA$5.2M
3
PCSAProcessa Pharmaceuticals, Inc.$5.3M
21
PULMPulmatrix, Inc.$5.3M
43
LIMNLiminatus Pharma, Inc.$4.7M
11
VIVSVivoSim Labs, Inc.$4.7M
33

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lakewood-Amedex Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LABT news & analysis

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

PRNewsWire · 8 Sept 2026neutral

Lakewood-Amedex Biotherapeutics announced that it will present at the H.C. Wainwright 28th Annual Global Investment Conference, with Kelvin Cooper, Ph.D. representing the company. The announcement was made via press release on September 8, 2026.

Why it matters — LABT watchers would care because the company presentation at a major investment conference provides exposure to investors and an opportunity for management to communicate its progress in developing its Bisphosphocin-class antimicrobials.

FAQ

Frequently asked questions about LABT stock

How does Ticker Nerd's model rank LABT?

As at 14 Sept 2026, Lakewood-Amedex Biotherapeutics, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

What is the LABT stock forecast for 2030?

No analyst covering Lakewood-Amedex Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LABT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

What does Lakewood-Amedex Biotherapeutics, Inc. do?

Lakewood-Amedex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing antimicrobial therapies for infectious diseases.

What is the latest news on LABT?

The most recent item we track (PRNewsWire, 8 Sept 2026): "Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference". Lakewood-Amedex Biotherapeutics announced that it will present at the H.C. Wainwright 28th Annual Global Investment Conference, with Kelvin Cooper, Ph.D. representing the company. The announcement was made via press release on September 8, 2026.

Company

About Lakewood-Amedex Biotherapeutics, Inc.

Lakewood-Amedex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing antimicrobial therapies for infectious diseases. Its current pipeline centers on the Bisphosphocin class, a novel group of broad-spectrum antimicrobials designed to address infections affecting the skin, bladder, lungs, and other serious bacterial conditions. The company’s lead program, Nu-3, is a topical antimicrobial being developed for infected diabetic foot ulcers, reflecting its emphasis on localized treatment options for hard-to-treat infections. Lakewood-Amedex Biotherapeutics also works on broader anti-infective applications aimed at antibiotic-resistant pathogens, positioning the company within the specialized biotechnology segment of the healthcare market. Headquartered in University Park, Florida, the company operates as a focused developer of next-generation antimicrobial products for unmet medical needs.

CEO Dr. Kelvin Cooper Ph.D. · 5 employees · United States · https://lakewoodamedex.com